Former premier Lin Chuan (林全) yesterday clarified that he would not be working to help promote government policies in his new role as chairman of TTY Biopharm Co (台灣東洋藥品).
He said that his efforts would be focused on elevating TTY Biopharm’s profile in international markets, and that success of the nation’s biotechnology sector is not dependent on any single company.
Market observers have been upbeat on Lin’s appointment to the helm of the pharmaceutical company, on expectations that he would work as a proponent of President Tsai Ing-wen’s (蔡英文) “five plus two” innovative industries plan, which includes the biotechnology sector.
As the Executive Yuan is not a regulator of industries, his appointment does not violate conflict of interest rules nor the revolving-door policy for government workers, Lin said at a news conference in Taipei.
“Not every former government worker aims to become a ‘guardian deity’ for businesses as they transition to the private sector,” Lin said.
Amid rapid consolidation among the world’s biggest pharmaceutical companies, Taiwanese biotechnology firms must be able to differentiate and distinguish themselves by specializing in a few chosen fields, he said.
Lin said that he and TTY Biopharm president Clark Hsiao (蕭英鈞) have set their sights on growing the firm’s revenue 10-fold to US$1 billion.
The company reported that sales last year rose 8.8 percent annually to NT$4.09 billion (US$138.39 million), driven by rising shipments of chemotherapy drugs from its contract manufacturing business.
Net income last year rose 7.5 percent annually to NT$1.35 billion, with earnings per share of NT$5.43, setting a new record high, the company said.
TTY Biopharm shares yesterday surged 8 percent to NT$109 before settling at NT$105.50, a 5 percent increase.
Lin’s appointment also spurred on rallies for several other biotechnology stocks during yesterday’s session, dealers said.
Sweeping policy changes under US Secretary of Health and Human Services Robert F. Kennedy Jr are having a chilling effect on vaccine makers as anti-vaccine rhetoric has turned into concrete changes in inoculation schedules and recommendations, investors and executives said. The administration of US President Donald Trump has in the past year upended vaccine recommendations, with the country last month ending its longstanding guidance that all children receive inoculations against flu, hepatitis A and other diseases. The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a drag that would likely dent revenues and
Global semiconductor stocks advanced yesterday, as comments by Nvidia Corp chief executive officer Jensen Huang (黃仁勳) at Davos, Switzerland, helped reinforce investor enthusiasm for artificial intelligence (AI). Samsung Electronics Co gained as much as 5 percent to an all-time high, helping drive South Korea’s benchmark KOSPI above 5,000 for the first time. That came after the Philadelphia Semiconductor Index rose more than 3 percent to a fresh record on Wednesday, with a boost from Nvidia. The gains came amid broad risk-on trade after US President Donald Trump withdrew his threat of tariffs on some European nations over backing for Greenland. Huang further
Macronix International Co (旺宏), the world’s biggest NOR flash memory supplier, yesterday said it would spend NT$22 billion (US$699.1 million) on capacity expansion this year to increase its production of mid-to-low-density memory chips as the world’s major memorychip suppliers are phasing out the market. The company said its planned capital expenditures are about 11 times higher than the NT$1.8 billion it spent on new facilities and equipment last year. A majority of this year’s outlay would be allocated to step up capacity of multi-level cell (MLC) NAND flash memory chips, which are used in embedded multimedia cards (eMMC), a managed
CULPRITS: Factors that affected the slip included falling global crude oil prices, wait-and-see consumer attitudes due to US tariffs and a different Lunar New Year holiday schedule Taiwan’s retail sales ended a nine-year growth streak last year, slipping 0.2 percent from a year earlier as uncertainty over US tariff policies affected demand for durable goods, data released on Friday by the Ministry of Economic Affairs showed. Last year’s retail sales totaled NT$4.84 trillion (US$153.27 billion), down about NT$9.5 billion, or 0.2 percent, from 2024. Despite the decline, the figure was still the second-highest annual sales total on record. Ministry statistics department deputy head Chen Yu-fang (陳玉芳) said sales of cars, motorcycles and related products, which accounted for 17.4 percent of total retail rales last year, fell NT$68.1 billion, or
RSS